2025-04-05 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Review

**0. Summary Statistics:**

Colgate-Palmolive (CL) is a leading global consumer products company specializing in oral hygiene, personal care, and home care products.  Over the analyzed period, CL's cumulative return lagged behind the S&P 500 (VOO).  Recent price action shows a slight downward trend, and while earnings are relatively stable,  key financial metrics exhibit some volatility.

**1. Performance Comparison & Alpha/Beta Analysis:**

Colgate-Palmolive's cumulative return of 40.67% significantly underperformed the S&P 500's 71.02% return.  This represents a current lag of -30.3%, placing it in the 53.1st percentile of its historical performance range relative to the S&P 500 (based on a historical range of -73.6% to 7.9%).

The Alpha/Beta analysis reveals inconsistent performance relative to the market. While positive alphas (outperformance) are observed in certain periods (2018-2020, 2019-2021, 2020-2022), other periods show negative alpha (underperformance). The Beta consistently remains above 0.1, indicating higher volatility than the market.  Market capitalization (Cap(B)) fluctuates over time.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 4.8% | -16.0% | 0.1 | 51.5 |
| 2016-2018  | -12.0% | 63.2% | -29.0% | 0.2 | 41.6 |
| 2017-2019  | 7.0% | 63.2% | -22.0% | -0.1 | 49.4 |
| 2018-2020  | 25.0% | 63.2% | -4.0% | 0.6 | 62.8 |
| 2019-2021  | 38.0% | 13.1% | -36.0% | 0.9 | 64.1 |
| 2020-2022  | 16.0% | 69.0% | -4.0% | 0.9 | 60.6 |
| 2021-2023  | 7.0% | 69.0% | -21.0% | 0.7 | 62.9 |
| 2022-2024  | 14.0% | 69.0% | -1.0% | 0.6 | 73.3 |
| 2023-2025  | 18.0% | 61.2% | 15.0% | 0.4 | 74.3 |


**2. Recent Price Action:**

* **Closing Price:** $91.66
* **Change from Previous Close:** -$4.52 (a significant drop of approximately 4.7%)
* **5-Day Moving Average:** $93.76
* **20-Day Moving Average:** $92.07
* **60-Day Moving Average:** $89.81

The price is below both the 5-day and 20-day moving averages, indicating a short-term bearish trend.  However, it is above the 60-day moving average, suggesting some longer-term support. The significant drop in price from the previous close warrants further investigation.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4693 (High Risk) indicating potential volatility.
* **RSI:** 52.89 (slightly above neutral; not oversold or overbought).
* **PPO:** 0.15 (positive, suggesting a bullish momentum, but relatively weak).
* **20-Day Relative Strength Change:** +18.7% (short-term upward trend).
* **Expected Return:** -40.5% (This is a significant negative expected return.  The context and methodology for calculating this needs clarification.)
* **Long-Term Expected Outperformance vs. S&P 500:**  This information is missing.


**4. Recent Earnings Analysis:**

The earnings data shows relatively stable revenue around $5B, with EPS showing minor fluctuation.  There's a slight downward trend in both EPS and revenue over the last few quarters. More detailed analysis (like YoY and QoQ comparisons) would provide greater insight.

| 날짜        | EPS | 매출          |
|-------------|-----|---------------|
| 2024-10-25  | 0.9 | $5.03 Billion |
| 2024-07-26  | 0.89 | $5.06 Billion |
| 2024-04-26  | 0.83 | $5.07 Billion |
| 2023-10-27  | 0.86 | $4.92 Billion |
| 2024-10-25  | 0.86 | $4.92 Billion | *(Duplicate Entry?)*


**5. Financial Information:**

The financial data shows relatively stable revenue, with consistent profit margins around 60%. However, the Equity and ROE figures display substantial quarter-to-quarter volatility, suggesting potential issues in capital management or accounting practices. Further investigation is required to understand these fluctuations.


| Quarter     | Revenue | Profit Margin | Equity  | ROE       |
|-------------|----------|---------------|---------|-----------|
| 2024-12-31 | $4.95B   | 60.30%        | $0.21B  | 348.58%   |
| 2024-09-30 | $5.03B   | 61.08%        | $0.43B  | 169.43%   |
| 2024-06-30 | $5.06B   | 60.62%        | $0.12B  | 594.31%   |
| 2024-03-31 | $5.07B   | 60.00%        | $0.23B  | 296.96%   |
| 2023-12-31 | $4.95B   | 59.60%        | $0.61B  | 117.90%   |


**6. Overall Conclusion:**

Colgate-Palmolive's recent performance has lagged the market, with a significant price drop in the last trading session. While earnings remain relatively stable, the high market risk indicator, volatile ROE, and significant negative expected return raise concerns. The substantial volatility in key financial metrics needs further investigation.  A more detailed analysis, including a deeper dive into the -40.5% expected return calculation and the fluctuations in equity and ROE, is recommended before making any investment decisions. The provided data suggests a cautious approach; further research is crucial to assess the long-term investment potential of CL.
